Hikma sells ex-Ben Venue factory in Bedford to Xellia
Hikma Pharmaceuticals will sell its manufacturing facilities previously owned by Ben Venue Laboratories based in Bedford, Ohio, to Xellia Pharmaceuticals. In 2014,…
Pharmaceuticals, Biotechnology and Life Sciences
Hikma Pharmaceuticals will sell its manufacturing facilities previously owned by Ben Venue Laboratories based in Bedford, Ohio, to Xellia Pharmaceuticals. In 2014,…
Kristina M. Capiak, CCRP has been promoted the Anavex Life Sciences Corp’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities.
Presage Biosciences, an oncology company has appointed Tachi Yamada and Christoph Lengauer to its board of directors.
Eli Lilly has gotten the U.S. Food and Drug Administration (FDA) approval for cancer drug Portrazza, which comes in a form of injection for intravenous use, 800 mg/50 mL, in combination with gemcitabine and cisplatin.
US FDA has given Lupin a go to market Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets.
Tiziana Life Sciences plc, the clinical stage biotechnology company focused on oncology and immunology related drugs, has appointed a banker Willy Simon as a non-executive director.
Abzena plc will buy Philadelphia-based The Chemistry Research Solution LLC (TCRS), a specialist contract chemistry and bioconjugation company, specialized in producing and analyzing antibody drug conjugates (DACs), for $15 million
Advanced Oncotherapy, the developer of proton therapy systems for cancer treatment, has appointed Professor Stephen Myers OBE, Head of Medical Applications at CERN, as Executive Chairman of its subsidiary ADAM S.A.
You must be logged in to post a comment.